ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT): what the price requires

At today's price, ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) is priced for today's economics sustained for ~21.4 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Source: https://boothcheck.com/report/ADPT

Headline

FieldValue
TickerADPT
CompanyADAPTIVE BIOTECHNOLOGIES CORPORATION
Current price$20.91/sh
CompositionMRD - Service revenue 70% / MRD - Regulatory milestone revenue 7% / Immune Medicine - Service and licensing revenue 8% / Immune Medicine - Collaboration revenue 15%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisrevenue-multiple
EV / sales paid12.7x
Steady-state operating margin assumed29.7%
Must persist for21.4y

The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.

Solve inputs: computed at a 14.5% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~3.2 years.

Reconcile: at the x-ray's 9.3% required return this reads ~8.7 years; the models below use their own rates.

How unusual the bet is: elevated

ReferenceValue
vs own history-0.29σ
sustained it ~10 years at this level14%
implied end-window share0%

Valuation X-Ray

Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset15.89x2expensive
Earnings—0—
Relative2.75x2expensive
Growth1.65x2expensive

Families that call it expensive: Asset, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.8%); the inversion above states its own rate.

Per-Model Detail (n=6)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$0.00—noNegative/zero FCF — equity value floored at $0
DCF Exit MultipleGrowth$0.00—noNegative/zero FCF or EBITDA — equity value floored at $0
Relative ValuationRelative$7.602.75xyesP/S fallback (negative EPS): Sector P/S 4.0x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$1.3915.04xyesBook value floor: BV/sh $1.39, ROE negative
Two-Stage Excess ReturnAsset$1.2516.73xyesBook value with convergence: BV/sh $1.39, ROE converges to ke
Discounted Future Market CapGrowth$30.340.69xyesRev $0.3B, growth 30% (input: historical growth; tapered), Terminal P/S: 8.8x / 11.0x / 13.2x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth$8.022.61xyesMargin ramp: -17% → 12% over 7yr, rev growth 30% (input: historical growth; tapered)
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$7.602.75xyesRevenue $0.30B × sector P/S 4.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net cash$87.8m
Interest coverage-5.4x
Share count CAGR (dilution)2.4%
Burning cashyes

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Bullet Takeaways

Bull Case

The market is pricing Adaptive as a speculative pre-profit biotech, and the fundamentals are quietly outgrowing that label. The clonoSEQ diagnostics business is not a science project; it is a commercial test with rising volume and improving economics. Full-year 2025 MRD revenue grew 46%, clonoSEQ test volume rose 39%, and the company guides to companywide positive adjusted EBITDA and positive free cash flow in 2026 with sequencing gross margins above 70%. That is the profile of a business crossing from investment-mode losses into self-funding profitability, and the negative trailing operating margin reflects the investment, not a broken model: high gross margins plus accelerating volume is exactly the combination that turns into operating leverage as scale arrives.

The moat is clinical adoption, which compounds slowly and then sticks. clonoSEQ measures minimal residual disease in blood cancers, the trace of disease left after treatment, and the more it appears in clinical guidelines and trials, the harder it is to dislodge. Its presence across major oncology conferences, dozens of presentations including plenary and oral sessions at ASCO and EHA in 2026, is the kind of evidence base that converts physician practice, and once a test is embedded in how oncologists make treatment decisions, the switching cost is the body of validation behind it. The Immune Medicine arm adds optionality through collaboration and licensing revenue with biopharma partners, a separate way the platform monetizes the same underlying immune-sequencing technology.

The planned separation is the bull's clarifying catalyst. Adaptive intends to split the profitable, fast-growing MRD diagnostics business from the earlier-stage Immune Medicine arm, with a preferred path identified by year-end 2026. A standalone MRD business, growing revenue in the mid-40-percent range with 70%-plus gross margins and approaching free-cash-flow breakeven, would be far easier for the market to value than a blended entity where the diagnostics profits subsidize the research losses. The bull case is that the value of clonoSEQ is hidden inside a conglomerate structure, and separation, plus the 2026 cash-flow inflection, is what surfaces it.

Bear Case

The capital-allocation history is the bear's starting point, because it explains why the share count keeps drifting up and why the balance sheet needs managing. Adaptive has funded years of losses, recently issued convertible notes to reshape its capital structure, and the share count has grown about 2.4% a year. Convertibles are a tell: a company confident in near-term self-funding does not usually need to add convertible debt, and the instrument dilutes existing holders if the stock rises into the conversion price. The planned separation of the MRD and Immune Medicine businesses, while strategically appealing, is also a costly, distracting undertaking whose terms, and the allocation of cash and the convertible obligation between the two pieces, are not yet known, and separations frequently create stranded costs and minority complexities that the clean bull narrative skips.

The operating risk is reimbursement, the perennial hazard of diagnostics. Adaptive warns that if payers do "not provide adequate reimbursement for, a substantial portion of the price of our diagnostic tests, we may need to seek payment from the patient," which can "adversely affect demand," delay revenue, and raise collection costs. A test can be clinically excellent and still be a poor business if payers will not pay for it at scale, and the company already provides tests at reduced rates through a patient-assistance program, which pressures the realized price per test. The Immune Medicine arm faces its own intensifying competition; the filing notes that "due to the significant interest and growth in immune medicine more broadly, we expect the intensity of the competition" to rise.

The valuation gives none of this any cushion. The company is still loss-making, so the price is set against sales, and at roughly 10 times revenue no valuation family reaches the price, not assets, not earnings, not peers, not even forward growth. Inverted, that price implies the business eventually earns a roughly 30% operating margin and grows revenue near its self-funding ceiling for close to two decades, a path only about 14% of comparable fast-growers sustained for even ten years. The bear case is not that clonoSEQ fails; it is that the price already assumes a long, smooth march to high-margin scale, financed without further meaningful dilution, in a reimbursement environment the company itself flags as a risk, and any stumble on the profitability inflection or the separation resets a valuation that has no static support beneath it.

Valuation

Because Adaptive does not yet earn an operating profit, the price has to be read against its sales, and on that basis it is demanding. At $17.54 (June 27, 2026) the stock trades at about 10 times revenue, and inverting that gives the bet in plain terms: the price implies the business eventually reaches an operating margin near 30% and grows revenue at roughly its self-funding ceiling for about 19 years. The historical base rate is sobering, only about 14% of comparable fast-growers sustained that kind of pace for even a decade. This is a price built on a long runway of high-margin growth that has not happened yet, which is the right frame for a diagnostics company at the cusp of profitability rather than past it.

That is why no valuation family reaches the price. The asset methods, anchored on a book value near $1.39 a share, sit far below it, and with negative earnings the earnings-power methods do not apply at all. Even the revenue-multiple lens, applying a sector price-to-sales multiple, lands below the price, and the forward-growth methods that credit a margin ramp still fall short. When every standard frame sits beneath the price, the price is a bet beyond what any of them supports, and the honest reading is that the market is paying for the clonoSEQ franchise to scale into a high-margin business, not for anything the current financials show. The cleaner way to think about the value is the planned separation: a standalone MRD business at 70%-plus gross margins and mid-40-percent revenue growth would carry a more defensible multiple than the blended, loss-making whole.

Solvency is the load-bearing question for a company still burning cash. Adaptive held about $227 million of cash and marketable securities at year-end 2025, against roughly $131 million of gross debt, including the convertible notes, so it has a multi-year runway at the current burn, and the guidance to positive free cash flow in 2026 would, if delivered, remove the financing overhang entirely. But the path runs through the reimbursement and competitive risks the company itself flags, and the share count has been rising. The downside is not bounded by asset value, which the methods put far below the price; it is bounded by the cash runway and the credibility of the 2026 cash-flow inflection. The decisive question is whether Adaptive reaches self-funding before it needs to raise again, because a loss-making company priced at ten times sales has the most to lose if the inflection slips.

Catalysts

The dominant catalyst is the planned business separation. Adaptive announced its intention to split the MRD diagnostics business from the Immune Medicine arm and expects to identify its preferred path to separation by year-end 2026. That decision, and its structure, is the single event most likely to re-rate the stock, because it would let the market value the profitable, fast-growing diagnostics franchise on its own terms.

The operating catalysts run through clonoSEQ and the 2026 cash-flow goal. Full-year 2025 MRD revenue grew 46% on clonoSEQ test volume up 39% to 105,587 tests, and the company guides to 2026 MRD revenue of $260 million to $270 million, more than 30% clinical volume growth, an average selling price around $1,400, sequencing gross margins above 70%, and companywide positive adjusted EBITDA and free cash flow. The clinical-evidence flywheel keeps turning: clonoSEQ featured in 33 presentations across the ASCO and EHA meetings in May 2026, including a plenary session and 14 oral presentations. Each quarterly volume and margin print is a read on whether the profitability inflection is on schedule.

Sentiment is constructive and clustered near the price. The covering analysts lean Buy, with a mean target close to the current level, around $20, reflecting confidence in the clonoSEQ momentum balanced against the execution risk of the separation and the path to self-funding. The variables to watch from here are the realized 2026 free-cash-flow result, the terms of the separation, and any reimbursement developments, because those are what convert the bull's profitability thesis into fact or expose the bear's runway concern.

Peer Cohorts (Per Segment, With Filing Citations)

MRD (reported)

Immune Medicine (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

company announcement, 2026 · company FY2026 guidance, 2026 · company announcement, May 2026 · analyst consensus, June 2026

View the full interactive ADPT report on boothcheck